

PCT
5000 PCT

In re Patent Application of

BLAKE et al

Serial No. 09/367,261

Filed: August 13, 1999

Title: DRUG TARGETING



Atty Dkt. 39-187

C#/M#

Group Art Unit:

Examiner:

Date: August 27, 1999

Honorable Commissioner of Patents
and Trademarks
Washington, DC 20231

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

Fees are attached as calculated below:

Total effective claims after amendment	0	minus highest number		
previously paid for	20	(at least 20) =	0	x \$ 18.00
				\$ 0.00
Independent claims after amendment	0	minus highest number		
previously paid for	3	(at least 3) =	0	x \$ 78.00
				\$ 0.00
If proper multiple dependent claims now added for first time, add \$260.00 (ignore improper)				\$ 0.00
Petition is hereby made to extend the current due date so as to cover the filing date of this paper and attachment(s) (\$ 110.00 /1 month; \$380.00/2 months; \$870.00/3 months)				\$ 0.00
Terminal disclaimer enclosed, add \$110.00				\$ 0.00
First submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$760.00)				\$ 0.00
Second submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$ 760.00)				\$ 0.00

☐ Please enter the previously unentered filed

SUBTOTAL \$ 0.00

If "small entity," then enter half (1/2) of subtotal and subtract
☐ Statement filed herewith

Rule 56 Information Disclosure Statement Filing Fee (\$240.00) \$ 0.00

Assignment Recording Fee (\$40.00) \$ 0.00

TOTAL FEE ENCLOSED \$ 0.00

The Commissioner is hereby authorized to charge any deficiency in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our **Account No. 14-1140**. A duplicate copy of this sheet is attached.

1100 North Glebe Road
8th Floor
Arlington, Virginia 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100
MJW:tat

NIXON & VANDERHYE P.C.

By Atty: Mary J. Wilson, Reg. No. 32,955

Signature: Mary J. Wilson

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION OF

BLAKE et al

Atty. Ref.: 39-187

Serial No.: 09/367,261

Group Art Unit:

Filed: August 13, 1999

Examiner:

For: **DRUG TARGETING**



* * * * *

August 27, 1999

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Hon. Commissioner of Patents
and Trademarks
Washington, DC 20231

Sir:

Attached is a PTO-1449 Form listing the documents cited in the International Search Report that should be substituted for that filed August 13, 1999. The attached Form corrects the publication number of the Senju Pharma Co. European case.

Respectfully submitted,

NIXON & VANDERHYE, P.C.

By

Mary J. Wilson

Mary J. Wilson
Reg. No. 32,955

MJW:tat

1100 North Glebe Road
8th Floor
Arlington, Virginia 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

**INFORMATION DISCLOSURE
CITATION**

ATTY. DOCKET NO.

39-187

SERIAL NO.

09/367,261

APPLICANT


BLAKE et al

FILING DATE

August 13, 1999

GROUP

(Use several sheets if necessary)


U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5 0 8 6 0 6 8	2/1992	Raleigh et al			
	5 3 8 7 6 9 2	2/1995	Riley et al			

FOREIGN PATENT DOCUMENTS

DOCUMENT		DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	
	0 650 763	6/1995	EP				
	WO 96 25147	8/1996	PCT				

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	Oellinger et al, "Study on the redox properties of naphthazarin (5,8-dihydroxy-1,4-naphthoquinone) and its glutathionyl conjugate in biological reactions: one- and two-electron enzymic reduction", <i>CHEMICAL ABSTRACTS</i> , VOL. 112, NO. 11, 12 March 1990, Columbus, Ohio, US; and <i>ARCH. BIOCHEM. BIOPHYS.</i> (1989).
	Firestone et al, "Nitro heterocycle reduction as a paradigm for intramolecular catalysis of drug delivery to hypoxic cells", <i>J. MED. CHEM.</i> (1991), 34(9).
	Chikhale et al, "Tumor targeted prodrugs: Redox-activation of conformationally constrained, bioreductive melphalan prodrugs", <i>EIGHTY-EIGHTH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH</i> , San Diego, California, USA, April 12-16, 1997. <i>PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING</i> (38 (0). 1997. 432-433.
	Mehta et al, "Potential bioreductively activated hypoxia probes and post-irradiation radiosensitizers related to NITP", <i>ANTI-CANCER DRUG DES.</i> (1995), 10(3), 227-41.
	Hodgkiss et al, "Pharmacokinetics and binding of the bioreductive probe for hypoxia, NITP: effect of route of administration", <i>BR. J. CANCER</i> , vol. 72, 1995, pages 1462-1468.
	Berglund, "Bioreductive Heterosubstituted Quinone Antitumor Drug Delivery Agents", <i>DATABASE DISSABS</i> , 1987.

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)